Truvian's TruVerus: FDA Clearance Brings Blood Tests to the Clinic

The wait for routine blood test results could soon be dramatically shortened. Truvian Health recently achieved a major milestone with FDA Clearance of their TruVerus™ platform for a total of 26 different tests, including the Complete Blood Count (CBC), the most frequently ordered routine blood test in the United States (over 400 million tests performed each year), along with cardiovascular, liver, and core metabolic health tests. As early-stage investors in Truvian, we are proud to see this pivotal milestone achieved.

Truvian has created a compact benchtop analyzer that brings blood tests previously limited to large central labs right into the clinic. Unlike traditional testing, where the blood sample is sent out to a central lab and patients can wait days for results, TruVerus delivers results in less than 30 minutes. TruVerus runs over two dozen of the most common and vital clinical blood tests from a single blood sample.

This capability is a game-changer for healthcare, empowering doctors to make immediate, informed decisions during a single visit. This shift enables a model of proactive, patient-first care, where treatment plans start faster and health is managed more efficiently. 

Truvian is not just advancing a technology, they are accelerating our journey toward a healthier, more responsive world.